Equity and Ethics
Equity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.
Key Insights
- 1
The inequities in clinical trial participation limit the understanding of how diverse populations respond to psychedelic therapies.
- 2
Initiatives like the Indigenous Reciprocity Initiative aim to ensure that Indigenous voices are integral to the psychedelic discourse and benefit-sharing.
- 3
The current designation of psychedelics as Schedule I substances poses barriers to research and increases costs, limiting their potential as accessible treatments.
- 4
Collaborative efforts between companies and Indigenous groups are essential for preserving traditional knowledge and ensuring fair profits from psychedelics.
- 5
Adopting an Open Science approach could facilitate wider access to psychedelic therapies by sharing knowledge and methodologies openly.
What is Equity and Ethics?
The field of psychedelics has faced significant ethical concerns, particularly regarding the representation and inclusion of diverse populations in clinical trials. Historical biases, such as the WEIRD bias, lead to a predominance of participants from Western, educated, industrialised, rich, and democratic backgrounds, undermining the generalisability of findings across different ethnic and cultural groups.
Indigenous communities, who have utilised these substances for centuries, are at risk of being excluded from the benefits of their cultural heritage as commercialization trends gain momentum. This further complicates the landscape, as modern psychedelic research often adapts traditional practices to fit Western medicine.
The legacy of the War on Drugs creates a psychological reluctance among racial minorities, particularly African Americans, to engage with psychedelic-assisted therapies. Addressing these issues is crucial to ensuring equitable access and reducing health disparities associated with mental health treatments.
Current Treatments
Standard treatments for mental health disorders include pharmaceuticals (e.g., SSRIs, SNRIs) and psychotherapy. However, psychedelic-assisted therapy is emerging as a potential alternative, poised to offer novel approaches alongside traditional treatments.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Equity and Ethics.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Ongoing trials show consistent therapeutic benefits in controlled studies, although evidence is still emerging. | Medium | Moderate | Consistent |
| MDMA MDMA-assisted therapy has undergone rigorous trials demonstrating significant efficacy in treating PTSD. | Large | High | Highly Consistent |
| Ayahuasca Research varies widely, with some studies showing potential benefits while others lack robust methodologies. | Medium | Moderate | Inconsistent |
| Ketamine Widely studied for its rapid antidepressant effects in treatment-resistant depression. | Large | High | Consistent |
Psilocybin and Equity and Ethics
Psilocybin is thought to facilitate profound psychological and emotional experiences that help alleviate anxiety and depression. Its efficacy in clinical trials for therapeutic use demonstrates its potential to assist individuals in processing traumatic memories and cultivating a renewed perspective on their mental health issues.
MDMA and Equity and Ethics
MDMA's unique mechanism of action enhances emotional connectivity and empathy, making it especially effective in psychotherapy for trauma. It is frequently administered in a therapeutic setting to facilitate discussions about past traumas and promote healing through interpersonal connection.
Ayahuasca and Equity and Ethics
Ayahuasca, traditionally used within Indigenous practices, induces vivid introspective experiences that can lead to significant psychological insights. While some evidence suggests its therapeutic potential in treating mood disorders, more rigorous research is needed to understand its mechanisms and ensure safe application within therapeutic contexts.
Ketamine and Equity and Ethics
Ketamine is increasingly recognised for its rapid antidepressant effects, particularly in treatment-resistant depression. Its ability to induce altered states of consciousness may provide novel pathways for addressing psychological distress and facilitating therapeutic breakthroughs.
Clinical Outlook
The future of psychedelic treatments largely hinges on addressing systemic inequities and fostering collaboration with Indigenous communities. As research evolves, integrating diverse perspectives will be paramount to developing holistic treatment models that benefit all individuals, particularly those historically marginalised in clinical research settings.
Industrial Landscape
Key organisations include the Chacruna Institute, Woven Science, Journey Colab, and the Indigenous Medicine Conservation Fund, all of which focus on upholding Indigenous rights and promoting equity in psychedelic therapy.
Quick Indicators
Organisations
Search →Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
University Hospital, Bonn
University hospital affiliated with the University of Bonn and one of Europe's leading academic medical centers. Its psychiatry and neuroscience departments have contributed to research on psychedelic-assisted therapies and novel treatments for mood and anxiety disorders.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Christopher Davoli
Associate Professor of Psychology at Central Michigan University
He is a cognitive psychologist whose work with colleagues has helped document acute and longer-term effects of psychedelics on perception, experience, and psychological outcomes.
Adam Winstock
Professor of Addiction Medicine; Consultant Psychiatrist and Founder/Director of Global Drug Survey
A leading figure in global survey-based research on psychedelics, club drugs, and substance use patterns, with widely cited work informing harm reduction and public health.
Elena Argento
Researcher and postdoctoral scholar at the University of British Columbia / BC Centre on Substance Use
Elena Argento is notable for community-based research on psychedelics, sexual health, and substance use, including studies on marginalized women, ayahuasca-assisted therapy, and potential psychedelic-related reductions in suicidality and opioid use.
Connected Evidence
The latest clinical data and verified academic findings associated with Equity and Ethics.